 NEW YORK, June 17, 2021 PRNewswire -- Actinium Pharmaceuticals, Inc. NYSE AMERICAN: ATNM Actinium or the Company today announced that its intellectual property portfolio around its lead Phase 3 candidate, Iomab-B, has been further strengthened internationally. In the EU, Actinium has been issued a patent covering the composition and methods administration of Iomab-B, an Antibody Radiation Conjugate ARC comprised of apamistamab, a CD45 targeting antibody, and the radioisotope iodine-131. 